Literature DB >> 22671573

Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: a preclinical study of cervical carcinoma and melanoma xenografts.

Kirsti Marie Øvrebø1, Christine Ellingsen, Tord Hompland, Einar K Rofstad.   

Abstract

BACKGROUND: Gadolinium diethylene-triamine penta-acetic acid (Gd-DTPA)-based dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been suggested to be a useful non-invasive method for providing biomarkers for personalized cancer treatment. In this preclinical study, we investigated whether Gd-DTPA-based DCE-MRI may have the potential to differentiate between poorly and highly metastatic tumors.
MATERIAL AND METHODS: CK-160 cervical carcinoma and V-27 melanoma xenografts were used as tumor models. Fifty-six tumors were imaged, and parametric images of K(trans) (the volume transfer constant of Gd-DTPA) and v(e) (the fractional distribution volume of Gd-DTPA) were produced by pharmacokinetic analysis of the DCE-MRI series. The host mice were examined for lymph node metastases immediately after the DCE-MRI.
RESULTS: Highly metastatic tumors showed lower values for median K(trans) than poorly metastatic tumors (p = 0.00033, CK-160; p < 0.00001, V-27). Median v(e) was lower for highly than for poorly metastatic V-27 tumors (p = 0.047), but did not differ significantly between metastatic and non-metastatic CK-160 tumors (p > 0.05).
CONCLUSION: This study supports the clinical attempts to establish DCE-MRI as a method for providing biomarkers for tumor aggressiveness and suggests that tumors showing low K(trans) and low ve values may have high probability of lymphogenous metastatic dissemination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22671573     DOI: 10.3109/0284186X.2012.689851

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

1.  Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.

Authors:  Allison F O'Neill; Lei Qin; Patrick Y Wen; John F de Groot; Annick D Van den Abbeele; Jeffrey T Yap
Journal:  J Neurooncol       Date:  2016-08-30       Impact factor: 4.130

2.  Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.

Authors:  Shujing Shi; Rui Wang; Yitian Chen; Haizhu Song; Longbang Chen; Guichun Huang
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

3.  Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas.

Authors:  I S Haldorsen; I Stefansson; R Grüner; J A Husby; I J Magnussen; H M J Werner; Ø O Salvesen; L Bjørge; J Trovik; T Taxt; L A Akslen; H B Salvesen
Journal:  Br J Cancer       Date:  2013-10-31       Impact factor: 7.640

Review 4.  Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy.

Authors:  Heidi Espedal; Tina Fonnes; Kristine E Fasmer; Camilla Krakstad; Ingfrid S Haldorsen
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

5.  Tumor Microenvironment Modifications Recorded With IVIM Perfusion Analysis and DCE-MRI After Neoadjuvant Radiotherapy: A Preclinical Study.

Authors:  François Lallemand; Natacha Leroi; Silvia Blacher; Mohamed Ali Bahri; Evelyne Balteau; Philippe Coucke; Agnès Noël; Alain Plenevaux; Philippe Martinive
Journal:  Front Oncol       Date:  2021-12-21       Impact factor: 6.244

6.  Pretreatment Dynamic Contrast-Enhanced MRI Improves Prediction of Early Distant Metastases in Patients With Nasopharyngeal Carcinoma.

Authors:  Shy-Chyi Chin; Chien-Yu Lin; Bing-Shen Huang; Ngan-Ming Tsang; Kang-Hsing Fan; Yi-Kang Ku; Cheng-Lung Hsu; Sheng-Chieh Chan; Shiang-Fu Huang; Cheng-He Li; Hsiao-Jung Tseng; Chun-Ta Liao; Ho-Ling Liu; Kyunghyun Sung
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.